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Abstract: Spain is one of the countries most affected by the COVID-19 pandemic. Although risk fac-
tors for severe disease are published, sex differences have been widely neglected. In this multicentre
study, we aimed to identify predictors of in-hospital mortality in men and women hospitalised with
COVID-19. An observational longitudinal study was conducted in the cohort of patients admitted
to four hospitals in Andalusia, Spain, from 1 March 2020 to 15 April 2020. Sociodemographic and
clinical data were collected from hospital records. The Kaplan–Meier method was used to estimate
30-day survival and multiple Cox regression models were applied. All analyses were stratified by
sex. A total of 968 patients were included (54.8% men, median age 67.0 years). In-hospital mortality
reached 19.1% in men and 16.0% in women. Factors independently associated with an increased
hazard of death were advanced age, higher CURB-65 score and not receiving azithromycin treatment,
in both sexes; active cancer and autoimmune disease, in men; cardiovascular disease and chronic lung
disease, in women. Disease outcomes and predictors of death differed between sexes. In-hospital
mortality was higher in men, but the long-term effects of COVID-19 merit further research. The
sex-differential impact of the pandemic should be addressed in public health policies.
Keywords: COVID-19; SARS-CoV-2; hospital mortality; risk factors; sex
1. Introduction
Since its discovery, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
has quickly spread across the globe causing devastating effects. With more than 3.8 million
confirmed cases and 80,000 reported deaths as of 30 June 2021 [1], the burden of disease
attributable to COVID-19 in Spain is among the highest in the world, not to mention the
indirect effects on other diseases. Coronavirus hit hardest in the first wave of the pandemic,
characterised by the lack of preparedness from a public health standpoint, the use of drugs
with insufficient evidence and, above all, an unprecedented health care collapse.
Int. J. Environ. Res. Public Health 2021, 18, 9018. https://doi.org/10.3390/ijerph18179018 https://www.mdpi.com/journal/ijerph
Int. J. Environ. Res. Public Health 2021, 18, 9018 2 of 16
Several studies have described the clinical spectrum of COVID-19. It ranges from
asymptomatic to severe acute respiratory syndrome (SARS) with a variety of complications
and, in worst cases, death. Such variability is not random: patients with obesity, chronic
conditions or malignancies, those aged > 60 years and immunocompromised hosts, among
others, are at higher risk of death [2]. Although many risk factors have been identified,
their contribution may not be the same in women and men. Ignoring sex differences
in COVID-19 mortality hampers our understanding of infection by SARS-CoV-2 and,
indirectly, neglects the importance of gender-based risk factors [3]. For example, previous
works have suggested that factors associated with COVID-19 outcomes are different in
men and women [4]. However, further research is warranted and several authors have
pointed to the need of studies stratified by sex [5].
Furthermore, geographical singularities must be considered. In the context of the first
epidemic wave, disparities among populations were shaped not only by their demography.
Social determinants of health [6]—material conditions, psychosocial circumstances and
behavioural factors—influenced the risk of infection among the exposed, while health sys-
tems (overload and changing protocols for diagnosis, admission and treatment) influenced
the risk of death among the infected. As a result, important differences were observed
across areas even in the same country [7]. To our knowledge, risk factors for in-hospital
mortality have been published so far from four Spanish regions [7–10].
Andalusia is the most populated region in Spain (8.4 million inhabitants). Despite not
being among the most affected regions in the first wave, it had up to 12,568 confirmed cases
as of 10 May 2020, of which 6209 were hospitalised and 1444 died [11]. Besides, limited
availability of resources—annual per capita expenditure on health care is the lowest in
the country (EUR 1262) [12]—has compromised the healthcare’s response to COVID-19.
In this multicentre study, our objectives were to describe the baseline characteristics and
to analyse the predictors of in-hospital mortality of adult men and women admitted to
four Andalusian public hospitals during the first wave of the pandemic.
2. Materials and Methods
2.1. Design and Setting
We conducted a retrospective cohort study, according to the STROBE guidelines [13]
(see Supplementary Material Table S1). The Andalusian Cohort of Hospitalized patients for
COVID-19 (ANCOHVID) [14] is a dynamic cohort of patients admitted to four Andalusian
public hospitals—Reina Sofía University Hospital (RSUH, Córdoba, Spain), San Cecilio
University Hospital (SCUH, Granada, Spain), Ciudad de Jaén University Hospital (CJUH,
Jaén, Spain) and Puerto Real University Hospital (PRUH, Cádiz, Spain)—from 1 March
2020 to 15 April 2020. All patients were followed since admission until death, discharge, or
six months after the date of first admission if they were still hospitalised. Therefore, the
date of end of follow-up was 15 October 2020. RSUH, SCUH and CJUH cover, altogether, a
population of one million people in large urban areas, while PRUH covers a population
of approximately 150,000 in mostly rural areas. Average life expectancy in the region was
82 years before the pandemic, with a 5-year gap between men (80) and women (85). These
public hospitals contain a large number of beds (RSUH, 1209; CJUH, 749; SCUH, 543;
PRUH, 319) and are part of the Spanish national health system, which provides universal
coverage to any of its residents.
Inclusion criteria of the study were: confirmed polymerase chain reaction (PCR) to
SARS-CoV-2 of nasal, pharyngeal, sputum or bronchoalveolar lavage sample, following
the Spanish Ministry of Health’s definition of confirmed cases [15] as of 1 March 2020, at
the beginning of the inclusion period; and age at diagnosis of 18 years or older.
2.2. Variables and Data Sources
We collected clinical data from hospital electronic health records. Sociodemographic
data were retrieved from primary care electronic health records. We then merged both
types of data in a pre-defined institutional database.
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The variables included in this study were: (a) sociodemographic characteristics: age
(years), sex and country of birth (native vs. non-native), place of residence and depen-
dency in activities of daily living (ADL); (b) chronic conditions: arterial hypertension,
diabetes, cardiovascular disease, chronic lung disease, chronic obstructive pulmonary
disease (COPD), non-allergic asthma (hereafter, asthma), chronic kidney disease, active
cancer (solid or hematologic malignancy), history of cancer in the previous 5 years, au-
toimmune disease, obesity, tobacco smoking, history of previous transplantation, and
HIV infection; (c) treatments received: polymedication (i.e., six or more prescribed drugs)
prior to admission, immunosuppressive therapy prior to admission, antimicrobial agents
(hydroxychloroquine, lopinavir-ritonavir, azithromycin and other antibiotics), immunosup-
pressants (tocilizumab and high-dose systemic corticosteroids); (d) clinical: abnormal chest
X-ray at admission, ferritin levels upon admission, acute distress respiratory syndrome
(ADRS), concurrent infection (coinfection or superinfection during hospitalisation), need
for mechanical ventilation (invasive—IMV and non-invasive—NIMV), length of hospital
stay and length of intensive care unit ICU) stay, and the CURB-65 severity score at the
time of hospital admission; (e) outcomes: admission to the ICU and death during hospital
stay (main outcome). We considered the main outcome for patients who died during the
first admission and for those readmitted due to COVID-19 who died during readmission.
Obesity, smoking and ADRS were excluded from the analyses because data were missing
in ≥25% of patients. Definitions of variables are presented in Supplementary Table S2.
2.3. Statistical Analyses
Qualitative variables were expressed as absolute numbers and their relative frequen-
cies. Normality of quantitative variables was assessed by the Shapiro-Wilk test, and they
were expressed as mean and standard deviation (SD) if normally distributed, or as median
and interquartile range (IQR) if not. In the bivariate analysis, we compared categorical
variables with Pearson’s chi-square test or Fisher’s exact test, when appropriate; and quan-
titative variables with Student’s t-test or Mann-Whitney U test, when appropriate. To
further characterise the profile of comorbidities among men and women who died during
hospital stay, we built correlation matrices to examine interdependencies between the main
chronic conditions in patients who had at least one of them.
We used the Kaplan-Meier method to estimate the probability of survival and the
log-rank test to compare survival between groups. In the multivariate analysis, all variables
associated with in-hospital mortality in the bivariate analysis with a p-value < 0.30 and
key comorbidities were included in two backward, multiple Cox regression models (one
per sex). Models were adjusted by age, ADL, chronic conditions, treatments received,
concurrent infection, need for mechanical ventilation and CURB-65 score. For each variable,
we used Schoenfeld residuals to verify the proportionality of hazards. Collinearity of the
model was measured by the variance inflation factors. Significance of the regression
coefficients was assessed by Wald’s test. All statistical tests were two-sided, and variables
with a p-value of 0.05 or less were considered significant. The analyses were performed
using R software version 4.0.3 (R Foundation for Statistical Computing, Vienna, Austria).
2.4. Ethical Considerations
The procedures described here were carried out in accordance with the ethical stan-
dards described in the Helsinki Declaration revised in 2013. Ethical approval was obtained
from the Provincial Research Ethics Committee of Granada (code 1585-N-20). Due to its
observational nature, the aforementioned committee exempted the need to seek written
informed consent. We utilized an anonymized database that was specifically designed for
this study and identifying variables were removed for analysis.
3. Results
After excluding one patient aged < 18 years, there were 530 men (55%) and 438 women
(45%) diagnosed with COVID-19 admitted to the participating hospitals. Their median age
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at admission was 67 years (range 18–100, interquartile range—IQR 55–77—but deceased
subjects were notably older (Figure 1).
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Figure 1. Distribution of all admitted patients (A), patients who died (B) and patients who survived (C), stratified by age
and sex.
Over one in five patients were dependent in ADL. The majority (72%) of patients had
at least one chronic condition, the most frequent of which was arterial hypertension (56%).
Almost half of patients (43%) were polymedicated prior to admission. Median CURB-
65 score upon admission was 1 (IQR 0–2), indicating low-severity, although patients who
died presented with a significantly higher risk (median 2, IQR 2–3). Hydroxychloroquine
(86%), and azithromycin (75%) were the most frequently prescribed drugs. During hospital
stay, 117 patients (12%) were admitted to the ICU and 171 (18%) died. Patient characteristics
are detailed in Table 1.
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Table 1. Characteristics of patients hospitalised with COVID-19, stratified by sex.













Age, years <0.001 < 0.001
<40 44 (5.5%) 0 (0.0%) 19 (4.4%) 1 (1.4%) 25 (6.8%)
40–49 93 (11.7%) 2 (2.0%) 50 (11.7%) 0 (0.0%) 43 (11.7%)
50–59 181 (22.7%) 8 (7.9%) 100 (23.3%) 0 (0.0%) 81 (22.0%)
60–69 207 (26.0%) 16 (15.8%) 120 (28.0%) 6 (8.6%) 88 (23.9%)
70–79 164 (20.6%) 30 (29.7%) 94 (21.9%) 15 (21.4%) 69 (18.8%)
80–89 95 (11.9%) 32 (31.7%) 39 (9.1%) 33 (47.1%) 56 (15.2%)
≥90 13 (1.6%) 13 (12.9%) 7 (1.6%) 15 (21.4%) 6 (1.6%)
Mean (IQR) 67 (55–77) 77 (68–84) 63 (54–72) 83 (77.5–88) 63 (52–75)
Country of birth 0.509 0.392
Non-native 36 (3.9%) 1 (1.0%) 34 (4.4%) 1 (1.5%) 19 (5.4%)
Centre 0.257 0.692
Granada (SCUH) 441 (45.6%) 52 (51.5%) 191 (44.5%) 28 (40.0%) 170 (46.2%)
Jaén (CJUH) 270 (45.6%) 26 (25.7%) 125 (29.1%) 20 (28.6%) 99 (26.9%)
Córdoba (RSUH) 220 (22.7%) 16 (15.8%) 95 (22.1%) 19 (27.1%) 90 (24.5%)
Cádiz (PRUH) 37 (3.8%) 7 (6.9%) 18 (4.2%) 3 (4.3%) 9 (2.5%)
Dependence in activities
of daily living 207 (21.5%) 41 (41.0%) 53 (12.4%) <0.001 47 (68.1%) 66 (18.0%) <0.001
Place of residence
Living at home 826 (85.6%) 72 (72.7%) 393 (91.8%) <0.001 42 (60.0%) 319 (86.7%) <0.001
Nursing homes 104 (10.9%) 24 (24.2%) 17 (4.0%) <0.001 26 (37.7%) 37 (11.5%) <0.001
Institutions for
disabled people 39 (4.1%) 3 (3.1%) 20 (4.7%) 0.594 3 (4.3%) 13 (3.6%) 0.731
Missing data 33 (3.4%)
Chronic conditions
No. of chronic conditions;
median (IQR) 1 (0–2) 2 (1–4) 1 (0–2) <0.001 2 (1–4) 1 (0–2) <0.001
Arterial hypertension 542 (56.0%) 75 (74.3%) 226 (52.7%) <0.001 56 (80.0%) 185 (50.3%) <0.001
Diabetes mellitus 226 (23.3%) 32 (31.7%) 95 (22.1%) 0.059 27 (38.6%9 72 (19.6%) <0.001
Cardiovascular disease 243 (25.1%) 46 (45.5%) 101 (23.5%) <0.001 32 (45.7%) 64 (17.4%) <0.001
Chronic lung disease 154 (15.9%) 29 (28.7%) 62 (14.5%) 0.001 19 (27.1%) 44 (12.0%) 0.002
COPD 65 (6.7%) 21 (20.8%) 36 (8.4%) <0.001 4 (5.7%) 4 (1.1%) 0.025
Asthma 69 (7.1%) 6 (5.9%) 24 (5.6%) 1.000 4 (5.7%) 35 (9.5%) 0.428
Chronic kidney disease 112 (11.6%) 21 (20.8%) 41 (9.6%) 0.003 23 (32.9%) 27 (7.3%) <0.001
Autoimmune disease 74 (7.6%) 9 (8.9%) 22 (5.1%) 0.222 4 (5.7%) 39 (10.6%) 0.299
Immunosuppression 41 (4.2%) 4 (4.0%) 16 (3.7%) 1.000 7 (10.0%) 14 (3.8%) 0.059
Polymedication (≥6
drugs prior to admission) 403 (42.6%) 59 (59.6%) 152 (36.3%) <0.001 49 (72.1%) 143 (39.7%) <0.001
Missing data 22 (2.3%)
Active cancer 50 (5.2%) 14 (13.9%) 20 (4.7%) 0.002 4 (5.7%) 12 (3.3%) 0.301
History of cancer in the
previous 5 years 62 (6.4%) 9 (8.9%) 35 (8.2%) 0.963 6 (8.6%) 12 (3.3%) 0.051
Solid organ or
HSC transplantation 10 (1.0%) 0 (0.0%) 6 (1.4%) 0.601 2 (2.9%) 2 (0.5%) 0.122
In-hospital variables
Length of stay (days);
median (IQR) 11 (7–17) 8 (4–15) 12 (8–18) <0.001 6 (4–11) 10 (7–17) <0.001
Length of ICU stay
(days); median (IQR) 12 (6–3.25) 13 (9–26) 13 (5.5–30) 0.533 10 (6–13) 12 (4.5–15) 0.840
Abnormal admission
















1 (0–2) 2 (1–3) 1 (0–1) <0.001 2 (2–3) 1 (0–2) <0.001
Low risk
(CURB-65 = 0–1) 493 (63.3%) 22 (25.9%) 252 (76.9%) 9 (16.1%) 209 (73.3%)
Medium risk
(CURB-65 = 2) 186 (24.6%) 34 (40.0%) 62 (18.8%) 23 (41.1%) 67 (23.5%)
High risk
(CURB-65 = 3–5) 76 (10.1%) 29 (34.1%) 14 (4.3%) 24 (42.9%) 9 (3.2%)
Missing data 213 (22.0%)
Concurrent infection 166 (22.0%) 41 (51.3%) 66 (20.2%) <0.001 13 (25.0%) 46 (15.6%) 0.143
Missing data 214 (22.1%)
Hydroxychloroquine 804 (86.3%) 61 (64.2%) 381 (92.3%) <0.001 39 (58.2%) 323 (90.5%) <0.001
Missing data 36 (3.7%)
High-dose corticosteroids 362 (41.1%) 50 (55.6%) 182 (46.4%) 0.148 27 (42.2%) 103 (30.8%) 0.100
Missing data 87 (9.0%)
Lopinavir-ritonavir 569 (62.0%) 54 (56.8%) 278 (68.0%) 0.052 26 (39.4%) 211 (60.6%) 0.002
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Missing data 50 (5.2%)
Azithromycin 680 (74.6%) 48 (53.3%) 317 (77.9%) <0.001 30 (47.6%) 285 (81.0%) <0.001
Missing data 56 (5.8%)
Other antibiotics 581 (65.1%) 63 (70.8%) 268 (67.9%) 0.680 41 (64.1%) 209 (60.8%) 0.720
Missing data 76 (7.9%)
Tocilizumab 100 (11.8%) 14 (16.1%) 58 (15.6%) 0.982 4 (6.8%) 24 (7.3%) 0.890
Missing data 120 (12.4%)
Invasive mechanical
ventilation 81 (8.4%) 23 (22.8%) 34 (7.9%) <0.001 7 (10.0%) 17 (4.6%) 0.084
Non-invasive mechanical
ventilation 88 (9.1%) 11 (10.9%) 49 (11.4%) 1.000 4 (5.7%) 24 (6.5%) 1.000
ICU admission 117 (12.1%) 25 (24.8%) 56 (13.1%) 0.005 9 (12.9%) 27 (7.3%) 0.192
CJUH, City of Jaén University Hospital; COPD, chronic obstructive pulmonary disease; CURB-65, prognostic scale based on blood urea
nitrogen, respiratory rate, blood pressure and age; HSC, hematopoietic stem-cell; ICU, intensive care unit; IQR, interquartile range; PRUH,
Puerto Real University Hospital; RSUH, Reina Sofía University Hospital; SCUH, San Cecilio University Hospital. Percentage of variables
with missing data are reported. a p-value of Mann–Whitney U test, chi-square test, or Fisher’s exact test, when appropriate.
3.1. Patient Characteristics
Most patients were native (96%), aged 65 years or older (54%) and lived at home
(86%). However, women were substantially more likely than men to be dependent in
ADL (26% vs. 18%, p = 0.003) and to live in nursing homes (15% vs. 8%, p = 0.001).
The most prevalent chronic conditions were arterial hypertension (56%), cardiovascular
disease (25%), diabetes mellitus (23%), chronic lung disease (16%), chronic kidney disease
(12%) and autoimmune disease (8%). Although their distribution was similar in men
and women, cardiovascular disease (28% vs. 22%, p = 0.045) and COPD (11% vs. 2%,
p < 0.001) were more frequent in men, whereas women suffered more frequently from
autoimmune disease (10% vs. 6%, p = 0.028) and asthma (9% vs. 6%, p = 0.068). Deceased
patients showed a significantly worse situation at baseline, regarding arterial hypertension,
cardiovascular disease, chronic lung disease and chronic kidney disease (in all of them,
p < 0.05 for both sexes). Among patients who died during hospital stay, the main positive
associations between chronic conditions differed by sex: in men, (a) arterial hypertension
with cardiovascular disease and (b) chronic kidney disease with active cancer; in women,
the combination of diabetes with either (a) cardiovascular disease or (b) chronic kidney
disease. Figure 2 shows all comorbidity correlations in deceased individuals.
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At admission, most patients (88%) had an abnormal chest X-Ray and increased ferritin
levels (median 478.2 µg/L), with deceased patients showing higher levels. Pneumonia
severity was low in two thirds of patients, according to the CURB-65 score upon admission
(median score of 2, IQR 0-2). Nevertheless, men who died showed a significantly higher
score than those who survived (high risk in 34% vs. 4%, medium risk in 40% vs. 19%,
low risk in 26% vs. 77%; p < 0.001). Even more flagrant differences were observed in
women (high risk in 43% of deceased women vs. 3%, of discharged women, medium
risk in 41% vs. 24%, low risk in 16% vs. 73%; p < 0.001). In total, 22% of patients de-
veloped concurrent infections, which were particularly frequent in deceased men (51%).
Regarding treatments for COVID-19, 86% of the total cohort received hydroxychloroquine,
75% azithromycin, 65% other antibiotics (mainly third-generation cephalosporins) and
41% systemic corticosteroids; only a minority (12%) were given tocilizumab. Hydrox-
ychloroquine, azithromycin and lopinavir-ritonavir were less frequently prescribed in
patients who died. A relevant number of patients (114, 12%) received mechanical ven-
tilation, with men needing IMV more often than women (11% vs. 5%, p = 0.005). With
respect to the study outcomes, severe disease was more frequent in men, as they were
twice as likely to be admitted to the ICU (15% vs. 8%, p = 0.001) and had a higher overall
in-hospital mortality rate (19% vs. 16%, p = 0.244). Sex differences remained constant across
age groups with the exception of those aged 90 years or older, of whom men had a lower
in-hospital mortality (65% vs. 71%).
3.2. Survival Analysis
Figure 3 shows the survival curve of inpatients with COVID-19 during the first 30 days
of follow-up, stratified by sex. The mortality rate was constant for men, whereas women
died within the first 2 weeks, after which the mortality rate stabilized.
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(log-rank test p = 0.690). We also performed the survival analysis of men and women with
COVID-19 stratified by CURB-65 score upon admission (Figure 4). Important differences
were observed among patients with low risk (LR, score 0–1) and those with medium or
high risk (MHR, score 2–5). Survival rate at day 30 in men was 80.1% in LR and 47.4% in
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MHR. In contrast, women with low risk kept an elevated survival rate throughout their
hospital stay: at day 30, it was 93.4% in LR and 57.8% in MHR (log-rank test p < 0.001 for
both sexes).




Figure 4. Survival analysis of men (top) and women (bottom), stratified by low (LR) or medium/high risk (MHR) accord-
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1.37–5.65), autoimmune disease (HR: 3.22, 95% CI: 1.55–6.69), CURB-65 score upon ad-
mission (HR:1.64 per additional point, 95% CI: 1.28–2.11) and azithromycin (HR: 0.53,
95% CI: 0.33–0.84) were associated with in-hospital mortality. In women, factors associated
with in-hospital mortality were: age (HR: 1.06 per additional year, 95% CI: 1.02–1.09),
cardiovascular disease (HR: 1.80, 95% CI: 1.02–3.18), chronic lung disease (HR: 1.84, 95% CI:
1.01–3.36), CURB-65 score upon admission (HR: 2.67 per additional point, 95% CI: 1.93–3.69)
and azithromycin (HR: 0.50, 95% CI: 0.29–0.88). Additionally, we performed a third Cox
regression model for all included patients (see Supplementary Material Table S3). The
concordance index of the models was 0.84 (men), 0.90 (women) and 0.85 (both sexes).
Table 2. Cox regression models for in-hospital mortality among men and women.
Predictors Crude HR
a
(95% CI) b p Value
c Adjusted HR
(95% CI) p Value
c
Men
Age (years) 1.08 (1.06–1.10) <0.001 1.05 (1.02–1.07) <0.001
Active cancer 2.26 (1.28–3.98) 0.005 2.78 (1.37–5.65) 0.005
Autoimmune disease 1.73 (0.87–3.43) 0.119 3.22 (1.55–6.69) 0.002
CURB-65 score 2.32 (1.88–2.86) <0.001 1.64 (1.28–2.11) <0.001
Azithromycin treatment 0.38 (0.61–2.30) <0.001 0.53 (0.33–0.84) 0.008
Women
Age (years) 1.09 (1.07–1.12) <0.001 1.06 (1.02–1.09) 0.002
Cardiovascular disease 3.00 (1.86–4.82) <0.001 1.80 (1.02–3.18) 0.044
Chronic lung disease 1.76 (1.02–3.02) 0.042 1.84 (1.01–3.36) 0.045
CURB-65 score 3.31 (2.54–4.32) <0.001 2.67 (1.93–3.69) <0.001
Azithromycin treatment 0.24 (0.15–0.40) <0.001 0.50 (0.29–0.88) 0.016
a Hazard ratio; b Confidence interval; c p-value of Wald’s test. The concordance index of the models was 0.84 for men and 0.90 for women.
4. Discussion
4.1. Predictors of In-Hospital Mortality
Characteristics of subjects included in this study resemble those reported in our
country [16,17], so our cohort may be reasonably representative of the target population.
The only remarkable differences were related to ICU admission: patients from our cohort
were more likely to receive critical care, mechanical ventilation (IMV and NIMV) and
tocilizumab. In-hospital mortality was somewhat lower than expected [18]: 19% in men and
16% in women. As regions where coronavirus struck earlier are usually overrepresented in
large studies, variability in healthcare pressure and availability of ICU beds may underlie
these disparities.
Advanced age is arguably the strongest risk factor for poor prognosis in COVID-19 [4].
In order not to lose information, we evaluated age as a continuous variable, finding a
risk increase per each additional year of 5% in men and 6% in women, which is higher
than most estimates reported [19]. A possible reason is the long average life expectancy in
Andalusia, especially in women (85 years before the pandemic). Sex is also an independent
risk factor for death [20]; a systematic review and meta-analysis estimated the chance of
dying in males as 60% higher than women’s [21]. However, such value must be interpreted
with caution as most studies included were Chinese and may not be generalizable to
our study population. Men in our cohort showed a slightly higher risk than women
(HR: 1.25, 95% CI: 0.88–1.77), but it cannot be concluded than male sex was associated with
mortality. In a Spanish nationwide study investigating gender-based differences in over
10,000 hospitalised patients, men had a similar risk of death to those in our cohort (HR: 1.29,
p < 0.001) [18]. A larger study examining the gender-related mortality of COVID-19 across
European countries also found a higher risk in men (RR: 1.60, p < 0.001 [22]. Therefore, an
insufficient statistical power might explain our results. A comprehensive discussion on
differences among sexes is shown in Section 4.2.
Women present with milder symptoms at admission [18], which may be associated
with disease outcomes. Although CURB-65 score upon admission was a strong predictor of
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in-hospital mortality in this study, its relevance differed strikingly between men and women
(64% vs. 167% risk increase per 1-point increase, respectively). CURB-65, validated for
community-acquired pneumonia (CAP) [23], has been widely used for predicting 30-day
mortality in CAP but is far from ideal—PSI predicts mortality slightly better (91% vs. 88%)
in patients with COVID-19 [24] and new scales have been developed for SARS-CoV-2
infection [25]. Yet, a study conducted in one of the participating hospitals [26] found that
CURB-65 score had an adjusted HR of death of 1.76 per 1-point increase.
Azithromycin lowered the risk of death in men and women from our cohort. It was
initially reported that this antibiotic reduced SARS-CoV-2 viral load, but unfortunately it
did not show efficacy in clinical trials [27] and is no longer recommended to treat COVID-
19. However, azithromycin might have improved the outcome of patients developing
concurrent infection. To test this hypothesis, a subgroup analysis was performed, find-
ing almost identical results in patients with and without concurrent infection. Beyond
their antimicrobial activity, macrolides are used in infections such as pneumonia for their
anti-inflammatory properties [28]. However, high-dose corticosteroids, which do have
evidence supporting their use in severe COVID-19 [29], are a more powerful tool to coun-
teract inflammation and were not associated with a reduction of in-hospital mortality.
Neither of the effects of macrolides justify our findings but a potential selection bias might:
azithromycin is more likely to be contraindicated in high-risk patients due to its side effects
(prolongation of the QT interval, hepatotoxicity and multiple drug interactions).
Autoimmune disease and active cancer increased the risk of dying in men, in relation
with an impaired immunity to infection. In women, cardiovascular disease and chronic
lung disease were associated with in-hospital mortality. Cardiovascular morbidity hinders
the prognosis of viral respiratory infections such as influenza [30], especially if thrombotic
complications [31] occur. Respiratory chronic conditions, particularly COPD, worsen the
outcomes of patients with COVID-19 by increasing viral susceptibility, disrupting ciliary
clearance and compromising pulmonary function [32]. All of these predictors have been
previously reported in Spain. For example, Poblador-Plou et al. [8] found that men with
COVID-19 receiving immunosuppressive agents or corticosteroids for chronic conditions
had a three-fold increase in the risk of death. However, most studies did not present
their results stratified by sex: Berenguer et al. [17] observed a moderate increase in the
hazard of death in patients with cancer; Muñoz-Rodríguez et al. [7] described similar
results for the association between cardiac pathology and mortality; and Gude-Sampedro
et al. [10] reported that risk of dying nearly doubled in patients with COPD. Of note, the
low correlation we found between cancer and autoimmune disease in men, as well as
that of cardiovascular disease and COPD in women suggests that specific associations of
comorbidities may not be useful to predict mortality.
Notwithstanding that we included few clinical variables, the overall concordance
(i.e., predictive accuracy) of the Cox regression models was high: in fact, its performance
regarding mortality was better than that of prognostic models from regional studies in our
country [10]. Even though complex scores based on clinical, analytical and radiological
data are obviously more refined, predicting mortality using sociodemographic variables,
chronic conditions and simple clinical information upon admission saves time—and time
outweighs accuracy when health systems collapse. These findings reveal the practical
implications of our work: to develop accurate risk scores adapted to the characteristics of
patients in our region and to support the decision-making process of patient care when
health care facilities are overwhelmed by the pandemic.
4.2. Sex and Gender Differences
Several sex-related biological factors influence COVID-19 susceptibility and severity.
Two enzymes are crucial in the access of SARS-CoV-2 to host cells show sex-specific
expression [33]. Transmembrane protease/serine subfamily member 2 (TMPRSS2) primes
the viral spike protein to facilitate its binding to angiotensin-converting enzyme 2 (ACE2),
which acts as the entry receptor. The density of ACE2 receptors in each tissue correlates to
Int. J. Environ. Res. Public Health 2021, 18, 9018 11 of 16
the damage inflicted by the virus, with the lower respiratory tract (type II pneumocytes)
constituting the main target [34].
The immune defence against SARS-CoV-2 appears to be of paramount importance.
Innate and adaptive immune response are more robust in females [35]. Activation of
antigen-presenting cells by toll-like receptors (TLRs) is a key element of innate immunity;
coronavirus can interfere with TLR7 signalling, but higher expression of TLR7 in females
reduces the inhibitory effect of the virus [36]. An excess of high-mobility group box 1
protein (HMGB1) induces release of interleukin-6 [37], a pro-inflammatory agent with a
protagonist role in the cytokine storm [38]. Differentially regulated among sexes, males
show higher levels of HMGB1 [39]. Another biomarker of disease severity, lymphopenia,
is also more frequent in male patients [40]. Furthermore, females produce higher titres of
serum IgG [41], which may help them control severe infection. In fact, male sex is one of
the factors behind prolonged viral shedding [42], despite the absence of sex differences in
viral load [43]. Altogether, women would possess better tools to tackle SARS-CoV-2.
In addition, some alternative explanations have been proposed. Sex hormones mod-
ulate cellular and humoral immunity responses against infection [44]. Oestrogens are
immune-stimulatory [45], while testosterone is immunosuppressive and may lead to
thrombotic complications by inducing platelet activation and aggregation [46]. Nonethe-
less, it plays a cardioprotective role in men [20]. Otherwise, females would have higher
endurance levels under stressful conditions [39]. Last, intestinal microbiota regulates the
testosterone levels and is affected by oestrogens [45]. Thus, the possible interaction between
SARS-CoV-2 and gut commensal bacteria [47] could be sex-biased.
Less attention has been drawn to psychosocial factors, such as gender, which is a
social determinant of health. Women live longer but have fewer healthy years, experi-
encing pain [48], certain diseases [49] and mental health problems [50] more often than
men. Women are also more vulnerable during epidemics for a variety of reasons: some risk
factors for mental health disorders (e.g., social isolation) are disproportionately frequent in
women [51]; the gender pay gap [52] and the barriers in the labour market compromise
women’s financial security in times of crisis; publications and public health documents
usually fail to address gender issues [53], for instance, by only taking into account one
modality of care (formal healthcare) [54]; access to specific treatments is delayed as women
are underrepresented in drug development research [55], and those pregnant or breastfeed-
ing are excluded from most clinical trials [56]. To further complicate matters, epidemics
exacerbate gender inequities—women take on the functions that the system can no longer
assume [57]—and the ongoing pandemic is not an exception [58].
Infection by SARS-CoV-2 is more frequent in women [59], perhaps because of a higher
degree of exposure to the virus, particularly in the first wave of the pandemic, when
shortage of protective equipment was common across countries [60]. Women account for
68% of healthcare professionals and 76% of the providers of informal care in Spain [61].
In contrast, differences in behavioural factors are detrimental to men, who wait longer
before seeking care [62] and consume addictive substances more frequently. Three in five
smokers in Spain are men [63], and tobacco use is correlated with COVID-19 prognosis.
Additionally, self-reported adherence to public health measures is lower in men [64].
The first wave of the pandemic witnessed gender-based consequences of coronavirus
disease and the implementation of lockdowns. Social disruption increased the risk of
suicide [65]; furthermore, it has been suggested that women particularly struggled to
maintain their mental wellbeing [51], which should not come as a surprise, given the
unique stress, fear and guilt that women carry during epidemics [66]. It is also worth
mentioning that lockdowns had indirect health effects on women, including: a considerably
higher rate of caesarean delivery [67], a lack of access to abortion [68] and a concerning
increase in gender-based violence [69].
As with mortality, identifying which factors account for differences in COVID-19
outcomes can be extraordinarily challenging. In the ANCOHVID cohort, systemic (fatigue
and musculoskeletal pain) and mental health sequelae (depressive and anxiety symptoms)
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after hospitalisation were significantly more frequent in women, whereas uncontrolled
glycaemia was more frequent in men [14]. Who is to blame, sex or gender? Probably
both, as they are closely intertwined [70,71]: without embracing the interrelation between
biological and social factors, it will be hard to fathom the differential impact of coronavirus
among men and women.
4.3. Strengths and Limitations
Our study presents several limitations. There are some weaknesses inherent to its
retrospective nature, such as the quality and completeness of information based on clinical
records. Obesity and smoking are associated with a poor prognosis of COVID-19; yet,
they could not be analysed in this study given the lack of data collected in most patients.
In our opinion, behavioural risk factors should be properly collected in clinical settings,
since they influence health and disease similarly to biological risk factors. Besides, nursing
homes were worst hit in the first wave of the pandemic in Spain [72]. Thousands of
institutionalized patients died in these facilities due to strict hospital admission criteria [73].
Thus, there is a risk of selection bias that would underestimate mortality. However, we
conducted a 6-month follow-up until October 2020 and believe that these findings are
useful for current literature, due to the paucity of data on sex differences and the course
of the pandemic. Finally, there is also a risk of confusion bias, since we did not adjust
for relevant risk factors with missing data (e.g., obesity) or that were not collected (e.g.,
cerebrovascular disease). However, we designed a study with a high external validity, as
it is multi-centred and has a large sample size; and a robust analysis of sex differences in
patients hospitalised with COVID-19.
5. Conclusions
We described the baseline characteristics, treatments received and main outcomes of
patients with COVID-19 admitted to four centres in Andalusia, Spain, in the first wave of
the pandemic. We analysed predictors of in-hospital mortality. In both sexes, advanced
age, higher CURB-65 score upon admission and not receiving treatment with azithromycin
increased the risk of death. Sex-specific risk factors were active cancer and autoimmune
disease in men, and cardiovascular disease and chronic lung disease in women.
In this study, men show higher rates of ICU admission and in-hospital mortality.
Nevertheless, this may not be the case in middle- and especially low-income countries,
where less research is conducted. Another topic that should be addressed in future studies
is the long-term impact of the pandemic, as it might be greater on women. Several
authors [58,74] have made a call to address the sex- and gender-specific long-run effects of
COVID-19 on population health: healthcare systems are facing the growing demand for care
and the mental health fallout [51]. To this end, governments must allocate resources [75] to
overcome barriers to health services access and expand social protection.
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